SCHEMBL267613

SCHEMBL267613

CCOc1cc(OC)cc(C(=O)OC)c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
POLB P06746 2/20 0.49
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
DPP4 P27487 2/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11156433 0.85 KDM4E (0.60) KDM4EPOLBALDH1A1HTTGAA
SCHEMBL24104379 0.83 KDM4E (0.44) KDM4EPOLBALDH1A1HTTGAA
SCHEMBL27009292 0.80 TDP1 (0.64) KDM4ETDP1KMT2AALDH1A1GAA
SCHEMBL26092548 0.79 KDM4E (0.45) KDM4EPOLBTDP1KMT2AALDH1A1
SCHEMBL23292495 0.78 MAPT (0.58) KDM4ETDP1KMT2AALDH1A1HTT
SCHEMBL268659 0.77 TDP1 (0.42) TDP1KMT2AALDH1A1HTTCYP2C19
SCHEMBL505813 0.77 KDM4E (0.53) KDM4EPOLBALDH1A1HTTGAA
SCHEMBL6879560 0.77 TDP1 (0.47) KDM4EPOLBTDP1KMT2AALDH1A1
SCHEMBL7781045 0.76 TSHR (0.50) KDM4EALDH1A1CYP1A2LMNAHPGD
SCHEMBL24104384 0.76 GAA (0.56) KDM4EPOLBALDH1A1GAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885POLB 3843/4885TDP1 4744/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885POLB 3761/4885TDP1 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.